Evidence map›Paper›PMID 42287389›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Outcome-driven dosimetry optimization for [

Jiaxi Hu, Robert Seifert, Carlos Vinicius Gomes, Yizhou Chen, Yibin Liu, Warissara Jutidamrongphan, Michelle Amon, Jiahui Wang, Song Xue, Axel Rominger and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiaxi HuDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.ORCID 0000-0002-8940-4727
Robert SeifertDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Carlos Vinicius GomesDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Yizhou ChenDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Yibin LiuDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Warissara JutidamrongphanDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Michelle AmonDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Jiahui WangDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Song XueDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Ali Afshar-OrmiehDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland.
Kuangyu ShiDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20 3010 Bern, Bern, Switzerland. kuangyu.shi@unibe.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeInternal dosimetry in radiopharmaceutical therapy (RPT) traditionally prioritizes methodological optimization driven by physical dose accuracy. However, even recommended multiple-time-point (MTP) dosimetry remains subject to uncertainties related to limited sampling schedules, pharmacokinetic, and curve-fitting modeling assumptions. In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [

methodsClinical and image data from 50 patients were retrospectively analyzed. Transient treatment-emergent adverse events (TEAEs) and prostate-specific antigen (PSA) response were monitored following CTCAE v5.0 and PCWG3. Cycle-level mean absorbed doses (MTPD

resultsBone marrow STP dosimetry correlated significantly with anaemia grading (1d-STPD

conclusionThe outcome-driven TP selection for Hänscheid-based STP dosimetry converges with the physics-based choice within 2-day p.i., the clinically driven approach offers an alternative and complementary strategy for dosimetry development and may facilitate its translation into clinical practice.

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantRadiometryRadiopharmaceuticalsAgedHumansMaleMiddle AgedProstate-Specific AntigenRadioisotopesRadiotherapy DosageRetrospective StudiesTime FactorsTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617RadioisotopesRadiopharmaceuticals[ 177 Lu]Lu-PSMA-617DosimetryProstate cancerRadiopharmaceutical therapyTheranostics

Identifiers

PMID42287389
PMCPMC13525968

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.